27 patents
Utility
Cassette encoding a FPV/brachyury fusion protein
12 Sep 23
The present invention relates to one or more promoters and/or expression cassettes that can be used for enhancing expression of a heterologous gene, such as Brachury.
Zengji Li, Alain Delcayre, Ryan Rountree
Filed: 28 Jul 16
Utility
Combination therapy for treating cancer with an antibody and intravenous administration of a recombinant MVA
15 Aug 23
The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient.
Hubertus Hochrein, Henning Lauterbach, José Medina Echeverz, Matthias Habjan
Filed: 14 Mar 22
Utility
Poxvirus vectors encoding HIV antigens, and methods of use thereof
15 Aug 23
Poxvirus vectors encoding a synthetic HIV envelope antigen and other HIV antigens, as well as compositions containing such poxvirus vectors and uses of such poxvirus vectors as vaccines to provide improved immunity against HIV, are provided.
Frank Wegmann, Johannes Petrus Maria Langedijk, Jerôme Hubertina Henricus Victor Custers, Viki Bockstal, Markus Kalla
Filed: 10 Dec 21
Utility
Compositions and methods for enhancing the stability of transgenes in poxviruses
23 May 23
Provided herein are recombinant poxviruses that are stable through successive passaging of the recombinant poxviruses.
Markus Kalla, Ryan Rountree, Ulrike Dirmeier
Filed: 5 Jul 21
Utility
Recombinant modified vaccinia virus ankara (MVA) equine encephalitis virus vaccine
7 Feb 23
The present invention relates to recombinant modified vaccinia virus Ankara (MVA) and to methods of using the same.
Robin Steigerwald, Markus Kalla
Filed: 4 Jan 21
Utility
Multivalent recombinant modified vaccinia virus ankara (MVA) vector encoding filovirus immunogens
24 May 22
The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses.
Ariane Volkmann, Robin Steigerwald, Hubertus Hochrein, Ulrike Dirmeier, Henning Lauterbach, Jürgen Hausmann
Filed: 27 Feb 20
Utility
Combination therapy for treating cancer with an intravenous administration of a recombinant MVA and an antibody
15 Mar 22
The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient.
Hubertus Hochrein, Henning Lauterbach, José Medina Echeverz, Matthias Habjan
Filed: 23 Aug 18
Utility
Poxvirus vectors encoding HIV antigens, and methods of use thereof
25 Jan 22
Poxvirus vectors encoding a synthetic HIV envelope antigen and other HIV antigens, as well as compositions containing such poxvirus vectors and uses of such poxvirus vectors as vaccines to provide improved immunity against HIV, are provided.
Frank Wegmann, Johannes Petrus Maria Langedijk, Jerôme Hubertina Henricus Victor Custers, Viki Bockstal, Markus Kalla
Filed: 14 Jun 18
Utility
Stable recombinant MVA vectors comprising modified RSV genes with reduced intramolecular recombinatorial activity
18 Jan 22
The invention relates to vectors comprising two or more homologous nucleotide sequences and methods for generating them.
Robin Steigerwald
Filed: 7 Sep 18
Utility
Methods and compositions for inducing protective immunity against filovirus infection
16 Nov 21
The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.
Ariane Volkmann, Robin Steigerwald, Ulrike Dirmeier, Maria Grazia Pau, Benoit Christophe Stephan Callendret, Lucy A. Ward
Filed: 17 Oct 19
Utility
MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen
16 Nov 21
Compositions and methods are described for generating an improved effective immune response against an immunogen in humans.
Benoit Christophe Stephan Callendret, Kerstin Luhn-Wegmann
Filed: 6 Apr 18
Utility
Recombinant modified vaccinia virus Ankara (MVA) foot and mouth disease virus (FMDV) vaccine
31 Aug 21
The present invention relates to modified poxviral vectors and to methods of making and using the same.
Robin Steigerwald, Markus Kalla
Filed: 15 Jun 16
Utility
Compositions and methods for enhancing the stability of transgenes in poxviruses
6 Jul 21
Provided herein are recombinant poxviruses that are stable through successive passaging of the recombinant poxviruses.
Markus Kalla, Ryan Rountree, Ulrike Dirmeier
Filed: 28 Sep 17
Utility
Stable virus-containing composition
6 Jul 21
Described herein are compositions and pharmaceutical compositions including poxviruses, in particular vaccinia virus such as modified vaccinia Ankara (MVA) virus, a sulfate salt at a concentration between about 5 mM and 300 mM and a buffer, wherein the composition has a pH of between about 6.0 and 8.5.
Ahmad Shakeb Sediq, Wouter Frank Tonnis, Martinus Anne Hobbe Capelle
Filed: 15 May 18
Utility
PR13.5 promoter for robust T-cell and antibody responses
8 Jun 21
The invention encompasses recombinant poxviruses, preferably modified Vaccinia Ankara (MVA) viruses, comprising a Pr13.5 promoter operably linked to a nucleotide sequence encoding an antigen and uses thereof.
Robin Steigerwald, Kay Brinkmann
Filed: 22 Nov 17
Utility
Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
1 Jun 21
Provided herein are Modified Vaccinia Ankara (MVA) vectors and adenovirus vectors encoding HBV antigens.
Daniel Boden, Helen Horton, Jean-Marc Edmond Fernand Marie Neefs, Soumitra Roy, Jerôme Hubertina Henricus Victor Custers, Roland Christian Zahn, Markus Kalla
Filed: 18 Dec 18
Utility
Methods and compositions for enhancing vaccine immune responses
13 Apr 21
Provided herein are immunogenic compositions comprising a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleic acid sequence encoding a CD40 ligand (CD40L) and a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increases T-cell immune responses specific for the heterologous disease-associated antigen when administered to a human host, and related methods and uses.
Henning Lauterbach, Hubertus Hochrein
Filed: 15 Mar 13
Utility
Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
16 Mar 21
Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses.
Cédric Cheminay, Robin Steigerwald, Paul Chaplin
Filed: 9 Jan 20
Utility
Methods and compositions for inducing protective immunity against a marburg virus infection
23 Feb 21
Compositions, vaccines and methods using a combination of adenovirus vectors and MVA vectors for inducing protective immunity against a Marburg virus infection are described.
Benoit Christophe Stephan Callendret, Ramon Roozendaal, Jutta Sytske Hartkoorn-Pasma, Ariane Volkmann, Robin Steigerwald, Ulrike Dirmeier
Filed: 14 Jul 17
Utility
Recombinant modified vaccinia virus Ankara (MVA) equine encephalitis virus vaccine
4 Jan 21
The present invention relates to recombinant modified vaccinia virus Ankara (MVA) and to methods of using the same.
Robin Steigerwald, Markus Kalla
Filed: 26 Jan 17